Pharming Group (NASDAQ:PHAR – Get Rating) reached a new 52-week high during trading on Wednesday . The company traded as high as $13.01 and last traded at $11.09, with a volume of 10 shares changing hands. The stock had previously closed at $11.40.
Wall Street Analyst Weigh In
Separately, TheStreet upgraded Pharming Group from a "d+" rating to a "c" rating in a research report on Monday, August 15th.
Get
Pharming Group alerts:
Pharming Group Stock Performance
The company has a market capitalization of $662.59 million, a P/E ratio of 27.81 and a beta of -0.32. The business has a 50-day moving average of $10.84 and a 200-day moving average of $9.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.40 and a quick ratio of 4.68.
Pharming Group (NASDAQ:PHAR – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.03. The company had revenue of $50.15 million during the quarter, compared to the consensus estimate of $51.99 million. Pharming Group had a return on equity of 8.98% and a net margin of 14.90%. On average, sell-side analysts anticipate that Pharming Group will post 0.03 EPS for the current year.
About Pharming Group
(Get Rating)
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
Further Reading
- Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
- 3 Reasons Snap Stock Could Snap Back
- Freshpet: A Fresh Time To Buy Into This Growth Story?
- Nomad Foods: A Defensive Stock on the Move
- The Market Is Suddenly All Ears on Warner Music Group
- Uber Stock Surge On The Back Of Profitabilty
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
Pharming Group (NASDAQ:PHAR – Get Rating) reached a new 52-week high during trading on Wednesday . The company traded as high as $13.01 and last traded at $11.09, with a volume of 10 shares changing hands. The stock had previously closed at $11.40.
在週三的交易中，輝瑞集團(納斯達克：PharGet評級)創下52周新高。該公司股價一度高達13.01美元，最新報11.09美元，成交量為10股。該股此前收盤價為11.40美元。
Wall Street Analyst Weigh In
Separately, TheStreet upgraded Pharming Group from a "d+" rating to a "c" rating in a research report on Monday, August 15th.
另外，華爾街在8月15日週一的一份研究報告中將Pharming Group的評級從“d+”上調至“c”。
Get
Pharming Group
alerts:
Pharming Group Stock Performance
The company has a market capitalization of $662.59 million, a P/E ratio of 27.81 and a beta of -0.32. The business has a 50-day moving average of $10.84 and a 200-day moving average of $9.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.40 and a quick ratio of 4.68.
該公司市值為6.6259億美元，市盈率為27.81倍，貝塔係數為-0.32。該業務的50日移動均線切入位在10.84美元，200日移動均線切入位在9.20美元。該公司的債務權益比為0.60，流動比率為5.40，速動比率為4.68。
Pharming Group (NASDAQ:PHAR – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.03. The company had revenue of $50.15 million during the quarter, compared to the consensus estimate of $51.99 million. Pharming Group had a return on equity of 8.98% and a net margin of 14.90%. On average, sell-side analysts anticipate that Pharming Group will post 0.03 EPS for the current year.
輝瑞集團(納斯達克：PharGet Rating)最近一次發佈季度收益報告是在8月4日(星期四)。該公司公佈本季度每股收益(EPS)為0.04美元，超出分析師普遍預期的0.01美元，超出0.03美元。該公司本季度營收為5015萬美元，而市場普遍預期為5199萬美元。輝瑞集團的股本回報率為8.98%，淨利潤率為14.90%。賣方分析師平均預計，Pharming Group本年度每股收益將為0.03股。
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
生物製藥公司Pharing Group N.V.開發蛋白質替代療法和精準藥物並將其商業化，用於治療美國、歐洲和國際上未得到滿足的罕見疾病和醫療需求。該公司的主導產品是Ruconest，一種用於治療急性遺傳性血管性水腫的重組人C1酯酶抑制劑。
Further Reading
- Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
- 3 Reasons Snap Stock Could Snap Back
- Freshpet: A Fresh Time To Buy Into This Growth Story?
- Nomad Foods: A Defensive Stock on the Move
- The Market Is Suddenly All Ears on Warner Music Group
- Uber Stock Surge On The Back Of Profitabilty
- 免費獲取StockNews.com關於Pharming Group的研究報告(Phar)
- Snap股票可能反彈的3個原因
- Freshket：一個新的時間來購買這個成長故事？
- Nomad Foods：一隻移動中的防禦性股票
- 市場突然全神貫注於華納音樂集團
- 優步股價在盈利的支持下飆升
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharming Group Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pharming Group和相關公司的最新新聞和分析師評級的每日簡要摘要。
